載入中
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
前收盤價
US$2.03
+US$0.04 · +2.01%
盤中時間採用ET。市場資料可能有所延遲。
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
日內區間
目前US$2.03
52週區間
目前US$2.03
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1385.8萬 USD | 1614.6萬 USD | — | — | — |
| 銷貨成本 | 238.8萬 USD | 47.5萬 USD | — | — | — |
| 毛利 | 1147萬 USD | 1567.1萬 USD | — | — | — |
| 研究與開發 | 7369.6萬 USD | 5874.7萬 USD | 4958.6萬 USD | 8612.9萬 USD | 5105.4萬 USD |
| 銷售、一般及管理費用 | 2219.4萬 USD | 2542萬 USD | 3261萬 USD | 3735.2萬 USD | 1866.3萬 USD |
| 營業費用 | 9589萬 USD | 1.05億 USD | 8219.6萬 USD | 1.23億 USD | 6971.7萬 USD |
| 利息收入 | 361萬 USD | 703.9萬 USD | 663萬 USD | 276.4萬 USD | 2.3萬 USD |
| 折舊和攤銷 | 451.1萬 USD | 298.2萬 USD | 192.7萬 USD | 70.9萬 USD | 64.7萬 USD |
| 營業利益 | −8442萬 USD | −8946萬 USD | −8219.6萬 USD | −1.23億 USD | −6971.7萬 USD |
| 淨利 | −7962.1萬 USD | −7733.1萬 USD | −7379萬 USD | −1.21億 USD | −7597.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.67
上漲空間 277.83%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI522.3萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF194.46萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB105.25萬0.01%108.2億 USD0.44%US$206.49+3.00%
iShares Micro-Cap ETFIWC30.6萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19萬0.16%1.17億 USD0.73%US$15.9402+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ1.26萬0.01%1.12億 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB6504.120.01%9320.36萬 USD1.19%US$110.98+5.68%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
